The FDA approved Eli Lilly's Foundayo (tirzepatide oral) today, marking a pivotal moment in the $100 billion weight loss medication market. The approval comes just six months after Novo Nordisk's oral Wegovy received clearance, setting up a direct head-to-head competition between pharmaceutical giants.

Clinical Trial Results

In Phase III trials involving 2,400 participants, Foundayo demonstrated an average weight loss of 11.2% over 68 weeks, compared to 2.1% with placebo. The results, published simultaneously in The New England Journal of Medicine, show Foundayo trailing slightly behind oral Wegovy's 12.8% efficacy rate.

"This approval represents the first real competition in the oral GLP-1 space. Patients will benefit from having alternatives, and market dynamics will inevitably drive down costs." — Dr. Amanda Rodriguez, Obesity Medicine Specialist

Pricing Strategy

Eli Lilly set Foundayo's list price at $1,200 per month, $200 less than oral Wegovy's $1,400 monthly cost. Industry analysts expect aggressive pricing competition as both companies vie for insurance formulary inclusion.

Market Impact

The approval triggered immediate market reactions:

  • Eli Lilly stock jumped 7.2% in after-hours trading
  • Novo Nordisk shares fell 3.8% on Copenhagen exchange
  • Compounding pharmacy stocks continued their decline, with Hims & Hers down an additional 5%

Clinical Considerations

Healthcare providers note key differences between the medications. Foundayo showed a slightly higher incidence of gastrointestinal side effects (68% vs 62% for oral Wegovy) but demonstrated better glycemic control in diabetic patients.

The approval also includes a comprehensive Risk Evaluation and Mitigation Strategy (REMS) requiring prescriber certification and patient counseling on potential thyroid risks.

Looking Ahead

With both oral options now available, the focus shifts to real-world effectiveness and insurance coverage decisions. Medicare coverage remains prohibited under current law, leaving millions of potential patients reliant on private insurance or out-of-pocket payments.

Eli Lilly plans to launch Foundayo in major metropolitan areas by June 2026, with national availability expected by September.